Conjugated complement cascade inhibitors

Details for Australian Patent Application No. 2004253474 (hide)

Owner Johnson and Johnson Pharmaceutical Research and Development, L.L.C.

Inventors Ali, Farah; Travins, Jeremy M.; Hufnagel, Heather Rae; Khalil, Ehab; Ballentine, Shelley K.; Bone, Roger F.; Leonard, Kristi A.; Subasinghe, Nalin

Agent Shelston IP

Pub. Number AU-B-2004253474

PCT Pub. Number WO2005/002627

Priority 60/484,854 03.07.03 US; 60/571,374 14.05.04 US; 10/869,430 16.06.04 US

Filing date 18 June 2004

Wipo publication date 13 January 2005

Acceptance publication date 23 December 2010

International Classifications

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

Event Publications

2 February 2006 PCT application entered the National Phase

  PCT publication WO2005/002627 Priority application(s): WO2005/002627

21 December 2006 Assignment before Grant

  Ortho McNiel Pharmaceutical, Inc. The application has been assigned to Johnson and Johnson Pharmaceutical Research and Development, L.L.C.

23 December 2010 Application Accepted

  Published as AU-B-2004253474

21 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253475-Leukocyte internalized peptide-drug conjugates

2004253473-Methods of inhibiting vascular permeability and apoptosis